Literature DB >> 31854156

Is Renal Denervation Using Radiofrequency a Treatment Option for the Ventricular Arrhythmia Following Acute Myocardial Infarction?

Young Soo Lee1.   

Abstract

Entities:  

Year:  2020        PMID: 31854156      PMCID: PMC6923229          DOI: 10.4070/kcj.2019.0361

Source DB:  PubMed          Journal:  Korean Circ J        ISSN: 1738-5520            Impact factor:   3.243


× No keyword cloud information.
Ventricular arrhythmia (VA) after myocardial infarction is the most important risk factor for sudden cardiac death. Sympathetic nerve overactivation and regional cardiac hyperinnervation plays an important role in the pathogenesis of ventricular tachyarrhythmias (VT).1) So, the decreased sympathetic activity may prevent and treat the VAs as a target of multiple drugs including β-blockers. The evidence for a major role of the sympathetic nervous system in triggering cardiac tachyarrhythmias provided the rationale for anti-adrenergic interventions such as left cardiac sympathetic denervation (LCSD)2) to treat the patients with long-QT syndrome and catecholaminergic polymorphic VTs. Similar to LCSD or percutaneous suppression of stellate ganglion, renal denervation (RDN) could reduce a body norepinephrine spillover by 42% and efferent muscle sympathetic nerve activity by 66%.3) Ukena et al.4) reported that RDN could reduce the arrhythmia burden in patients with heart failure with refractory VT. Also, Hoffmann et al.5) reported the effect of RDN following VT ablation in the VT patient after acute myocardial infarction (AMI). In the issue of the Korean Circulation Journal, Kim et al.6) reports that RDN might reduce the incidence of premature ventricular complex (PVC), prolongation of the QT interval, and VA during acute phase in the porcine AMI model. Even though authors describe the efficacy of RDN using radiofrequency through increased serum norepinephrine level and histology (hematoxylin and eosin staining) around renal artery, tyrosine hydroxylase staining for cholinergic nerve is needed for achieving the successful RDN. Authors demonstrated that successful RDN is achieved by catheter-based RDN using radiofrequency ablation. However, unsolved issues are still remained in the technical and procedural aspects. In terms of technical points, the renal nerve anatomy has played an important role in the development of the RDN technique. The most RDN studies poorly described the site of energy delivery. The efficacy of RDN could be dependent on the nerve abundance near the ablation sites and the renal nerve anatomy in each individual.7) Steigerwald et al.8) demonstrated that the renal nerve are homogenously distributed throughout the renal artery and renal artery nerves are mostly found in the proximal segment of the renal artery and decreased gradually distally in the animal studies. In the part of procedural point, complete RDN with radiofrequency may be difficult to cause irreversible nerve damage due to inconsistent circumferential denervation and inadequate depth for energy delivery.9) Recently, some physicians tried to overcome these limitations. They investigated other catheter-based approaches such as ultrasound, cryogenic balloon or chemical RDN. The peri-adventitial injection of ethanol has been studied to perform a chemical RDN. In addition, electrical high frequency renal nerve stimulation (RNS) has been developed for a more physiological and electrophysiological approach to RDN. The RNS is used to map the sympathetic nerve tissue around renal artery by causing an electrical stimulation-induced blood pressure response to localize sympathetic nerves as ablation target sites. Although catheter-based RDN have limitations such as less uniform ablation technique and no definite procedural end-point, modulation of the renal nerve activity by RDN could be a reasonable therapeutic option in cardiovascular disease caused by increased sympathetic activity such as drug-resistant hypertension, atrial or VAs and heart failure.
  9 in total

1.  Renal sympathetic-nerve ablation for uncontrolled hypertension.

Authors:  Markus P Schlaich; Paul A Sobotka; Henry Krum; Elisabeth Lambert; Murray D Esler
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

2.  Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model.

Authors:  Kristin Steigerwald; Anna Titova; Caroline Malle; Elisabeth Kennerknecht; Clemens Jilek; Jörg Hausleiter; Jörg M Nährig; Karl-Ludwig Laugwitz; Michael Joner
Journal:  J Hypertens       Date:  2012-11       Impact factor: 4.844

3.  Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension.

Authors:  Abraham R Tzafriri; John H Keating; Peter M Markham; Anna-Maria Spognardi; James R L Stanley; Gee Wong; Brett G Zani; Debby Highsmith; Patrick O'Fallon; Kristine Fuimaono; Felix Mahfoud; Elazer R Edelman
Journal:  Sci Transl Med       Date:  2015-04-29       Impact factor: 17.956

4.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

5.  Renal sympathetic denervation as an adjunct to catheter ablation for the treatment of ventricular electrical storm in the setting of acute myocardial infarction.

Authors:  Boris A Hoffmann; Daniel Steven; Stephan Willems; Karsten Sydow
Journal:  J Cardiovasc Electrophysiol       Date:  2013-07-25

6.  Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry.

Authors:  Christian Ukena; Felix Mahfoud; Sebastian Ewen; Andreas Bollmann; Gerhard Hindricks; Boris A Hoffmann; Dominik Linz; Dan Musat; Valerie Pavlicek; Eberhard Scholz; Dierk Thomas; Stephan Willems; Michael Böhm; Jonathan S Steinberg
Journal:  Clin Res Cardiol       Date:  2016-06-30       Impact factor: 5.460

Review 7.  Management of Patients with Long QT Syndrome.

Authors:  Yongkeun Cho
Journal:  Korean Circ J       Date:  2016-10-20       Impact factor: 3.243

8.  Effect of Renal Denervation on Suppression of PVC and QT Prolongation in a Porcine Model of Acute Myocardial Infarction.

Authors:  Sung Soo Kim; Hyun Kuk Kim; Hyung Wook Park; Myung Ho Jeong; Kyung Seob Lim; Hae Jin Kee; Yu Hee Ryu; Han Byul Kim; Joo Young Na; Young Jae Ki; Keun Ho Park; Dong Hyun Choi; Ki Hong Lee; Nam Sik Yoon; Jeong Gwan Cho
Journal:  Korean Circ J       Date:  2019-08-23       Impact factor: 3.243

Review 9.  Idiopathic Polymorphic Ventricular Tachycardia: a "Benign Disease" with a Touch of Bad Luck?

Authors:  Sami Viskin
Journal:  Korean Circ J       Date:  2017-05-25       Impact factor: 3.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.